Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB).

It targets a lipopolysaccharide transporter.

[1] It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate.

[2] The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.

[3][4][5]